276 related articles for article (PubMed ID: 21185361)
1. Histone deacetylases in skeletal development and bone mass maintenance.
McGee-Lawrence ME; Westendorf JJ
Gene; 2011 Mar; 474(1-2):1-11. PubMed ID: 21185361
[TBL] [Abstract][Full Text] [Related]
2. Histone deacetylases in control of skeletogenesis.
Westendorf JJ
J Cell Biochem; 2007 Oct; 102(2):332-40. PubMed ID: 17661352
[TBL] [Abstract][Full Text] [Related]
3. Histone Deacetylases in Bone Development and Skeletal Disorders.
Bradley EW; Carpio LR; van Wijnen AJ; McGee-Lawrence ME; Westendorf JJ
Physiol Rev; 2015 Oct; 95(4):1359-81. PubMed ID: 26378079
[TBL] [Abstract][Full Text] [Related]
4. Regulation of Osteoclast Differentiation and Skeletal Maintenance by Histone Deacetylases.
Faulkner B; Astleford K; Mansky KC
Molecules; 2019 Apr; 24(7):. PubMed ID: 30959867
[TBL] [Abstract][Full Text] [Related]
5. Histone deacetylases (HDAC) in physiological and pathological bone remodelling.
Cantley MD; Zannettino ACW; Bartold PM; Fairlie DP; Haynes DR
Bone; 2017 Feb; 95():162-174. PubMed ID: 27913271
[TBL] [Abstract][Full Text] [Related]
6. Hdac-mediated control of endochondral and intramembranous ossification.
Bradley EW; McGee-Lawrence ME; Westendorf JJ
Crit Rev Eukaryot Gene Expr; 2011; 21(2):101-13. PubMed ID: 22077150
[TBL] [Abstract][Full Text] [Related]
7. Inhibitors of histone deacetylases in class I and class II suppress human osteoclasts in vitro.
Cantley MD; Fairlie DP; Bartold PM; Rainsford KD; Le GT; Lucke AJ; Holding CA; Haynes DR
J Cell Physiol; 2011 Dec; 226(12):3233-41. PubMed ID: 21344383
[TBL] [Abstract][Full Text] [Related]
8. Zfp521 controls bone mass by HDAC3-dependent attenuation of Runx2 activity.
Hesse E; Saito H; Kiviranta R; Correa D; Yamana K; Neff L; Toben D; Duda G; Atfi A; Geoffroy V; Horne WC; Baron R
J Cell Biol; 2010 Dec; 191(7):1271-83. PubMed ID: 21173110
[TBL] [Abstract][Full Text] [Related]
9. Regulation of Runx2 by Histone Deacetylases in Bone.
Vishal M; Ajeetha R; Keerthana R; Selvamurugan N
Curr Protein Pept Sci; 2016; 17(4):343-51. PubMed ID: 27072566
[TBL] [Abstract][Full Text] [Related]
10. Histone deacetylases 1 and 2 inhibition suppresses cytokine production and osteoclast bone resorption in vitro.
Algate K; Haynes D; Fitzsimmons T; Romeo O; Wagner F; Holson E; Reid R; Fairlie D; Bartold P; Cantley M
J Cell Biochem; 2020 Jan; 121(1):244-258. PubMed ID: 31222845
[TBL] [Abstract][Full Text] [Related]
11. Regulation of Histone Deacetylases by MicroRNAs in Bone.
Shreya S; Malavika D; Priya VR; Selvamurugan N
Curr Protein Pept Sci; 2019; 20(4):356-367. PubMed ID: 30381072
[TBL] [Abstract][Full Text] [Related]
12. The Deletion of Hdac4 in Mouse Osteoblasts Influences Both Catabolic and Anabolic Effects in Bone.
Nakatani T; Chen T; Johnson J; Westendorf JJ; Partridge NC
J Bone Miner Res; 2018 Jul; 33(7):1362-1375. PubMed ID: 29544022
[TBL] [Abstract][Full Text] [Related]
13. Using Histone Deacetylase Inhibitors to Analyze the Relevance of HDACs for Translation.
Hutt DM; Roth DM; Marchal C; Bouchecareilh M
Methods Mol Biol; 2017; 1510():77-91. PubMed ID: 27761814
[TBL] [Abstract][Full Text] [Related]
14. The many roles of histone deacetylases in development and physiology: implications for disease and therapy.
Haberland M; Montgomery RL; Olson EN
Nat Rev Genet; 2009 Jan; 10(1):32-42. PubMed ID: 19065135
[TBL] [Abstract][Full Text] [Related]
15. Effects of histone deacetylase inhibitor Scriptaid and parathyroid hormone on osteocyte functions and metabolism.
Sun N; Uda Y; Azab E; Kochen A; Santos RNCE; Shi C; Kobayashi T; Wein MN; Divieti Pajevic P
J Biol Chem; 2019 Jun; 294(25):9722-9733. PubMed ID: 31068415
[TBL] [Abstract][Full Text] [Related]
16. Histone Deacetylase 3 Deletion in Mesenchymal Progenitor Cells Hinders Long Bone Development.
Feigenson M; Shull LC; Taylor EL; Camilleri ET; Riester SM; van Wijnen AJ; Bradley EW; Westendorf JJ
J Bone Miner Res; 2017 Dec; 32(12):2453-2465. PubMed ID: 28782836
[TBL] [Abstract][Full Text] [Related]
17. Histone Deacetylases (HDACs): Evolution, Specificity, Role in Transcriptional Complexes, and Pharmacological Actionability.
Milazzo G; Mercatelli D; Di Muzio G; Triboli L; De Rosa P; Perini G; Giorgi FM
Genes (Basel); 2020 May; 11(5):. PubMed ID: 32429325
[TBL] [Abstract][Full Text] [Related]
18. Class 1-Selective Histone Deacetylase (HDAC) Inhibitors Enhance HIV Latency Reversal while Preserving the Activity of HDAC Isoforms Necessary for Maximal HIV Gene Expression.
Zaikos TD; Painter MM; Sebastian Kettinger NT; Terry VH; Collins KL
J Virol; 2018 Mar; 92(6):. PubMed ID: 29298886
[TBL] [Abstract][Full Text] [Related]
19. Histone Deacetylases in Kidney Physiology and Acute Kidney Injury.
Hyndman KA
Semin Nephrol; 2020 Mar; 40(2):138-147. PubMed ID: 32303277
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of histone deacetylases in cancer therapy: lessons from leukaemia.
Ceccacci E; Minucci S
Br J Cancer; 2016 Mar; 114(6):605-11. PubMed ID: 26908329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
